Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

NCT05303844 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Refractory Malignant Ascites

Interventions

DRUG: H101
DRUG: Tislelizumab

Sponsor

Fudan University